Differentiating subtypes of dementia in Parkinson’s disease


REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 The Sydney Multicentre Study of Parkinson’s disease was initially a prospective 5-year trial comparing low-dose bromocriptine (< 30 mg/day) and low-dose levodopa-carbidopa (< 600/150 mg/day) in 149 previously untreated patients (mean age 62 years) with Parkinson’s disease (Hely et al. Med J Aust 1987;146:195-198).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page